EUVIMEDEUVIMED entdecken
Fallbericht

Methotrexate Polyglutamates Exposure – Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

Renske C F Hebing iD, Imke H Bartelink iD, Helen R Gosselt iD, Sandra G Heil iD, Mauritis C F J de Rotte iD, Pascal H P de Jong iD, Mike T Nurmohamed iD, Robert de Jonge iD, Ron A A Mathôt iD

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2974 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Renske C F Hebing und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam Rheumatology and Immunology Center, Amsterdam UMC Location Reade, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate polyglutamates (MTX‐PG) concentrations in red blood cells (RBCs) have been suggested as a biomarker of response in patients with rheumatoid arthritis (RA) receiving low‐dose MTX therapy. We investigated the association and interpatient variability between RBC‐MTX‐PG 3‐5 ‐exposure and response in patients with RA starting MTX. Data of three prospective cohorts were available. The relationship between exposure and Disease Activity Score in 28 joints (DAS28) was analyzed using a population pharmacokinetic‐pharmacodynamic model. Relevant covariates were tested using full covariate modeling and backward elimination. From 395 patients, 3,401 MTX‐PG concentrations and 1,337 DAS28 measurements were available between 0 and 300 days after MTX treatment onset. The developed model adequately described the time course of MTX‐PG 3‐5 and DAS28. The median MTX‐PG 3‐5 level at month 1 was 30.9 nmol/L (interquartile range (IQR): 23.6–43.7; n = 41) and at month 3: 69.3 nmol/L (IQR: 17.9–41.2; n = 351). Clearance of MTX‐PG 3‐5 from RBCs was 28% lower (95% confidence interval (CI): 23.6–32.8%) in a woman and 10% lower (95% CI: 7.7–12.4%) in a 65‐year‐old compared with a 35‐year‐old patient. MTX‐PG 3‐5 concentrations associated with DAS28: half‐maximal effective concentration (EC 50 ) was 9.14 nmol/L (95% CI: 4.2 nmol/L‐14.1 nmol/L). EF at 80% (EC 80 ) above 47 nmol/L was regarded as the optimal response. Independent of the MTX‐PG 3–5 – response association, co‐administration of disease‐modifying antirheumatic drugs and corticosteroids improved response (additive effect on maximum effect ( E max )), whereas smoking, high body mass index and low albumin decreased E max . In patients with RA starting MTX, RBC‐MTX‐PG 3‐5 was associated with clinical response. A dose increase is suggested when MTX‐PG 3‐5 at month 1 is below 9.15 nmol/L, continued with the same dose when the concentration is above 47 nmol/L, and consider other treatment options above 78 nmol/L from 3 months onwards.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsFemaleHumansAgedAdultMethotrexateProspective StudiesTreatment OutcomeDrug Therapy, CombinationPolyglutamic Acid

Substanzen

MethotrexateAntirheumatic Agentsmethotrexate polyglutamatePolyglutamic Acid

Autor:innen und Institutionen

  • Amsterdam Rheumatology and Immunology Center, Amsterdam UMC Location Reade, Amsterdam, The Netherlands.
  • Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Clinical Chemistry, Amsterdam University Medical Center - Location VUmc, Amsterdam, The Netherlands.
  • Department of Clinical Chemistry, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Renske C F Hebing, Imke H Bartelink, Helen R Gosselt, Sandra G Heil, Mauritis C F J de Rotte, Pascal H P de Jong, Mike T Nurmohamed, Robert de Jonge, Ron A A Mathôt

Zitieren

APA

Hebing, R. C. F., Bartelink, I. H., Gosselt, H. R., Heil, S. G., de Rotte, M. C. F. J., de Jong, P. H. P., Nurmohamed, M. T., de Jonge, R., & Mathôt, R. A. A. (2023). Methotrexate Polyglutamates Exposure – Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2974

Vancouver

Hebing RCF, Bartelink IH, Gosselt HR, Heil SG, de Rotte MCFJ, de Jong PHP, et al. Methotrexate Polyglutamates Exposure – Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2974

BibTeX
@article{Hebing2023,
  author = {Hebing, Renske C F and Bartelink, Imke H and Gosselt, Helen R and Heil, Sandra G and de Rotte, Mauritis C F J and de Jong, Pascal H P and Nurmohamed, Mike T and de Jonge, Robert and Mathôt, Ron A A},
  title = {Methotrexate Polyglutamates Exposure – Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2974}
}
Kostenlos starten →